Factors Sustaining Tobacco Abstinence in Cancer Patients Treated With Radio-chemotherapy or Radiotherapy

Last updated: March 16, 2026
Sponsor: Centre Oscar Lambret
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Diabetes Prevention

Stimulant Use Disorder

Smoking Cessation

Treatment

Chemoradiotherapy or radiotherapy alone

Clinical Study ID

NCT06910566
TABAC STOP ORL POUMON-20-001
2020-A02912-37
  • Ages > 18
  • All Genders

Study Summary

The TABAC STOP ORL POUMON study aims to evaluate the factors influencing long-term smoking cessation in patients with head and neck cancer (HNC) or lung cancer undergoing radiotherapy or chemoradiotherapy. This is a single-center observational study, following patients at 1, 6, and 12 months after treatment completion. The primary objective is to determine the proportion of abstinent patients at 6 months, while secondary objectives analyze factors influencing abstinence, smoking trajectories, and reasons for relapse. A total of 100 patients will be included to ensure robust statistical analysis.

Eligibility Criteria

Inclusion

Inclusion Criteria :

  • Patient aged 18 years or older

  • Diagnosed with head and neck cancer or lung cancer

  • Undergoing curative treatment with chemoradiotherapy, radiotherapy alone, or stereotactic radiotherapy

  • Current or former smoker

  • Patient covered by a social security scheme

  • Patient informed and having given consent for data collection

Patients with human papillomavirus (HPV) may also be included

Exclusion Criteria :

  • Patient receiving palliative treatment

  • Patient under guardianship or curatorship

Study Exit Criteria :

  • Protocol-defined exit : After the 12-month consultation

Early exit :

  • Withdrawal of consent for data collection

  • Death of the patient

Study Design

Total Participants: 100
Treatment Group(s): 1
Primary Treatment: Chemoradiotherapy or radiotherapy alone
Phase:
Study Start date:
March 28, 2022
Estimated Completion Date:
November 30, 2026

Study Description

The TABAC STOP ORL POUMON study is a prospective, single-center observational study aiming to understand factors influencing long-term smoking cessation in patients treated for head and neck or lung cancer. Tobacco is a leading cause of death and disease, particularly in areas like Hauts-de-France with high smoking rates.

Eligible patients, undergoing radiotherapy or chemoradiotherapy, are enrolled during the final week of treatment, completing questionnaires assessing nicotine dependence and alcohol use. Follow-ups are scheduled at 1, 6, and 12 months, through clinic visits or phone interviews.

The primary endpoint is the proportion of patients who remain smoke-free at 6 months. Secondary endpoints include factors influencing smoking cessation, reasons for relapse, and changes in nicotine and alcohol dependence. The study will enroll 100 patients, expecting 81 evaluable cases, with data quality ensured through regular checks and source verification.

Connect with a study center

  • Centre Oscar Lambret

    Lille, 59020
    France

    Site Not Available

  • Centre Oscar Lambret

    Lille 2998324, 59020
    France

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.